BMY News and Press, Bristol-Myers Squibb Company From 02/27/26

2026-02-27 15:00:32 ET More on the markets Fed Rate Cuts On Hold, But Liquidity Conditions Still Look Supportive For Stocks They Said Stocks Would Only Return 6%, They Were Wrong Follow Rates Of Change To Be Ahead Of The Curve In 2026 Private credit default r...

2026-02-26 13:35:52 ET More on leading drugmakers Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie Johnson & Johnson: Strong Run May Be Ending (Rating Downgrade) Merck: Why Investors Should Remain Bullish Despite Patent Risks ...

2026-02-26 07:54:26 ET More on Bristol-Myers Squibb Bristol-Myers: I'm Buying Post Earnings Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength Bristol-Myers: Walking Blindfolded To A $30 Billion Patent Cliff Bristol Myers a new sector perform at...

Izalontamab brengitecan (Iza-bren) met its dual primary endpoints of progression free survival (“PFS”) and overall survival (“OS”) in an interim analysis of a Phase 3 trial (NCT06382142) conducted in China BL-B01D1-307 is the third Phase III study in which ...

2026-02-25 10:03:10 ET Shares of skin disease concern Oruka Therapeutics, Inc. ( ORKA ) have more than doubled since its IL-23p19 antagonist ORKA-001 demonstrated a half-life four times greater than Skyrizi in a Phase 1 study. The once or twice-yearly psoriasis candidate is undergoi...

2026-02-25 09:11:51 ET More on Bristol Myers Squibb Bristol-Myers: I'm Buying Post Earnings Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength Bristol-Myers: Walking Blindfolded To A $30 Billion Patent Cliff CDC Deputy Director Ralph Abraham ste...

NYSE Content Update: Two MSCI Indexes to Begin Trading on NYSE Arca Options PR Newswire NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK , Feb. 25, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directl...

2026-02-24 18:03:46 ET Trung Huynh from RBC Capital issued a price target of $60.00 for BMY on 2026-02-24 21:03:00. The adjusted price target was set to $60.00. At the time of the announcement, BMY was trading at $61.6. The overall price target consensus is at $62.50 wit...

2026-02-24 17:15:04 ET RBC Capital analyst issues SECTOR PERFORM recommendation for BMY on February 24, 2026 09:03PM ET. BMY was trading at $61.6 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst recommendations are : 19 - Buy,...

2026-02-24 09:35:33 ET Late-Stage Pipeline Advancements and Novel Therapies Position Sector for Accelerated Growth and Major Value Catalysts New York, NY –February 24, 2026 – Market News Updates News Commentary – Mental health disorders—in...